Effects of Atomoxetine in Mild Cognitive Impairment
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of atomoxetine and its effect primarily
on the biologic markers (substances that may indicate the presence of a disease) in the
cerebrospinal fluid (CSF) of participants diagnosed with Mild Cognitive Impairment (MCI).
Additionally, information will be gathered to identify the dose of atomoxetine that is most
beneficial, and how taking this medication affects thinking and behavior, as well as imaging
and blood biomarkers.The study will also explore rates of change in biomarkers of
neurodegeneration (Aß, tau, brain atrophy rates). The results of this research will help
determine if atomoxetine alters signs of inflammation and other biomarkers associated with
Alzheimer's disease.